This is well illustrated by the TP53 mutation status in our 96 tumor samples: although 50% of tumors with more aggressive subtypes (triple-negative, HER2-enriched, and luminal B HER2+) had mutations in TP53, less aggressive luminal B and luminal A subtypes included only 12.5% and 0.0% of TP53-mutated tumors, respectively (Data S1B). This evidence concerns the gene ERBB2 and neoplasm.